Multifunctionality of PAI-1 in fibrogenesis:: Evidence from obstructive nephropathy in PAI-1-overexpressing mice

被引:117
|
作者
Matsuo, S
López-Guisa, JM
Cai, XH
Okamura, DM
Alpers, CE
Bumgarner, RE
Peters, MA
Zhang, GQ
Eddy, AA
机构
[1] Univ Washington, Dept Pediat, Seattle, WA 98105 USA
[2] Childrens Hosp & Reg Med Ctr, Seattle, WA 98105 USA
[3] Univ Washington, Dept Pathol, Seattle, WA 98105 USA
[4] Univ Washington, Dept Microbiol, Seattle, WA 98105 USA
关键词
interstitial fibrosis; plasminogen activator inhibitor-1; macrophage; urokinase; unilateral ureteral obstruction;
D O I
10.1111/j.1523-1755.2005.00327.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Plasminogen activator inhibitor-1 (PAI-1) has been implicated in the pathogenesis of chronic kidney disease based on its up-regulated expression and on the beneficial effects of PAI-1 inhibition or depletion in experimental models. PAI-1 is a multifunctional protein and the mechanisms that account for its profibrotic effects have not been fully elucidated. Methods. The present study was designed to investigate PAI-1-dependent fibrogenic pathways by comparing the unilateral ureteral obstruction model (UUO) (days 3, 7, and 14) in PAI-I-overexpressing mice (PAI-1 tg) to wild-type mice, both on a C57BL6 background. Results. Following UUO, total kidney PAI-1 mRNA and/or protein levels were significantly higher in the PAI-1 tg mice (N = 6 to 8/group) and fibrosis severity was significantly worse (days 3, 7, and 14), measured both as Sirius red-positive interstitial area (e.g., 10 +/- 3.2% vs. 4.5 +/- 1.0%) (day 14) and total kidney collagen (e.g., 11.1 +/- 1.7 vs. 6.2 +/- 1.3 mu g/mg) (day 14). By day 14, the expression of two normal tubular proteins, E-cadherin and Ksp-cadherin, were significantly lower in the PAI-1 tg mice (3.2 +/- 0.5% vs. 11.7 +/- 5.9% and 2.6 +/- 1.6) vs. 6.2 +/- 0.8%, respectively), implying more extensive tubular damage. At least four fibrogenic pathways were differentially expressed in the PAI-1 tg mice. First, interstitial macrophage recruitment was more intense (P < 0.05 days 3 and 14). Second, interstitial myofibroblast density was greater (P < 0.05 days 3 and 7) despite similar numbers of proliferating tubulointerstitial cells. Third, transforming growth factor-beta 1 (TGF-beta 1) and collagen I mRNA were significantly higher. Finally, urokinase activity was significantly lower (P < 0.05 days 7 and 14) despite similar mRNA levels. Gene microarray studies documented that that the deletion of this single profibrotic gene had far-reaching consequences on renal cellular responses to chronic injury. Conclusion. These data provide further evidence that PAI-1 is directly involved in interstitial fibrosis and tubular damage via two primary overlapping mechanisms: early effects on interstitial cell recruitment and late effects associated with decreased urokinase activity.
引用
收藏
页码:2221 / 2238
页数:18
相关论文
共 47 条
  • [1] Chronic allograft nephropathy:: expression and localization of PAI-1 and PPAR-γ
    Revelo, MP
    Federspiel, C
    Helderman, H
    Fogo, AB
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (12) : 2812 - 2819
  • [2] PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction
    Oda, T
    Jung, YO
    Kim, HS
    Cai, XH
    López-Guisa, JM
    Ikeda, Y
    Eddy, AA
    KIDNEY INTERNATIONAL, 2001, 60 (02) : 587 - 596
  • [3] PAI-1: cardiac friend or foe?
    Miles, Lindsey A.
    Parmer, Robert J.
    BLOOD, 2010, 115 (10) : 1862 - 1863
  • [4] Plasminogen activator inhibitor-1 (PAI-1) 4 G/5 G polymorphism and endometrial cancer. Influence of PAI-1 polymorphism on tissue PAI-1 antigen and mRNA expression and tumor severity
    Gilabert-Estelles, Juan
    Ramon, Luis A.
    Braza-Boils, Aitana
    Gilabert, Juan
    Chirivella, Melitina
    Espana, Francisco
    Estelles, Amparo
    THROMBOSIS RESEARCH, 2012, 130 (02) : 242 - 247
  • [5] Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy
    Pontrelli, Paola
    Rossini, Michele
    Infante, Barbara
    Stallone, Giovanni
    Schena, Antonio
    Loverre, Antonia
    Ursi, Michele
    Verrienti, Raffaella
    Maiorano, Annamaria
    Zaza, Glanluigi
    Ranieri, Elena
    Gesualdo, Loreto
    Ditonno, Pasquale
    Bettocchi, Carlo
    Schena, Francesco Paolo
    Grandaliano, Giuseppe
    TRANSPLANTATION, 2008, 85 (01) : 125 - 134
  • [6] Plasminogen activator inhibitor-1 (PAI-1) expression in endometriosis
    Alotaibi, Fahad T.
    Peng, Bo
    Klausen, Christian
    Lee, Anna F.
    Abdelkareem, Amr O.
    Orr, Natasha L.
    Noga, Heather
    Bedaiwy, Mohamed A.
    Yong, Paul J.
    PLOS ONE, 2019, 14 (07):
  • [7] Prognostic importance of the uPA/PAI-1 complex in breast cancer
    Sten-Linder, M
    Seddighzadeh, M
    Engel, G
    Rutqvist, LE
    Linder, S
    Skoog, L
    Wiman, B
    ANTICANCER RESEARCH, 2001, 21 (4B) : 2861 - 2865
  • [8] Inhibition of PAI-1 attenuates perirenal fat inflammation and the associated nephropathy in high-fat diet-induced obese mice
    Liu, Yong
    Wang, Lin
    Luo, Mao
    Chen, Ni
    Deng, Xin
    He, Jing
    Zhang, Liping
    Luo, Pei
    Wu, Jianbo
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2019, 316 (02): : E260 - E267
  • [9] Plasminogen activator inhibitor-1 (PAI-1) is cardioprotective in mice by maintaining microvascular integrity and cardiac architecture
    Xu, Zhi
    Castellino, Francis J.
    Ploplis, Victoria A.
    BLOOD, 2010, 115 (10) : 2038 - 2047
  • [10] The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer
    Yildirim, Malik Ejder
    Karakus, Savas
    Kurtulgan, Hande Kucuk
    Kilicgun, Hasan
    Ersan, Serpil
    Bakir, Sevtap
    BIOCHEMICAL GENETICS, 2017, 55 (04) : 314 - 321